When does the Rytary patent expire?
The patent for Rytary (carbidopa-levodopa) is set to expire in November 2028 [1]. This date is based on the expiry of U.S. Patent No. 9,750,758 [1].
What is Rytary used for?
Rytary is a medication used to treat the symptoms of Parkinson's disease, including stiffness, tremors, and slowness of movement [2]. It is a combination of carbidopa and levodopa, which are used to increase the levels of dopamine in the brain [2].
How does Rytary work?
Levodopa is a precursor to dopamine, a neurotransmitter that is deficient in Parkinson's disease. Carbidopa helps to prevent the breakdown of levodopa in the bloodstream, allowing more of it to reach the brain [2]. Rytary utilizes an extended-release formulation, meaning it is designed to release the active ingredients over a prolonged period [2].
What happens when Rytary's patent expires?
Upon patent expiration, generic versions of Rytary may become available. This could potentially lead to lower medication costs for patients and increased competition in the market [3]. DrugPatentWatch.com tracks patent expiries and potential generic entry dates for various medications, including those for Parkinson's disease [4].
Are there other carbidopa-levodopa medications?
Yes, other formulations of carbidopa-levodopa are available, including immediate-release and other extended-release versions. The availability and specific release mechanisms of these alternatives can vary [2].
Who manufactures Rytary?
Rytary is manufactured by Amneal Pharmaceuticals [2].
---
Sources
1. DrugPatentWatch.com. (n.d.). Rytary Patent Expiration. Retrieved from https://drugpatentwatch.com/
2. Rytary. (n.d.). Rytary Official Website. Retrieved from [Insert actual website link if available and permitted by instructions]
3. U.S. Food & Drug Administration. (n.d.). Generic Drugs: Questions & Answers. Retrieved from [Insert actual FDA link if available and permitted by instructions]
4. DrugPatentWatch.com. (n.d.). Parkinson's Disease Drug Patents. Retrieved from https://drugpatentwatch.com/